Doctor versus AI for timing the IVF egg maturation trigger
Official title: Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm - A Randomized Control Study.
Run by FertilAI · NCT07110285 · Data updated 2026-11-12
This test sees if using an AI algorithm instead of a doctor to choose the trigger day produces more mature eggs during a GnRH-antagonist IVF stimulation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | FertilAI Industry-sponsored |
| Locations | 1 site (Herzliya) |
| Status | Recruiting |
| Started | May 21, 2025 |
| Main results expected | May 2027 |
| Study ends | May 21, 2028 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT07110285 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People undergoing ovarian stimulation with a GnRH antagonist for egg freezing or for IVF with ICSI where oocytes will be denuded and maturity recorded are ideal candidates.
✕Probably not a fit
Patients using non-antagonist stimulation protocols, those whose oocytes are not denuded so maturity cannot be assessed, or patients who withdraw from follow-up are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares the number of mature oocytes retrieved from ovarian stimulation cycles using a GnRH antagonist when trigger-day decisions are made by treating physicians versus an artificial intelligence algorithm. Eligible participants are patients undergoing stimulation for oocyte cryopreservation or for fertilization via ICSI where oocytes are denuded and maturity can be assessed. Cycles follow standard antagonist protocols and maturity is measured after oocyte denudation, with the primary outcome being the count of mature oocytes. The trial is sponsored by FertilAI and conducted at Herzliya Medical Center.
Why it matters
Potential benefit: If successful, the approach could increase the number of mature oocytes collected, potentially improving IVF or fertility preservation outcomes.
How similar studies have gone: AI tools have shown promise in embryo selection and cycle predictions, but using AI specifically to time the trigger day is relatively new with limited published evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed). Exclusion Criteria: * Loss to follow-up, patient retracts consent to participate
Where it's running
-
Herzliya Medical Center
Herzliya, Israel Recruiting
Study contacts
- Principal investigator: Ariel Hourvitz, MD — Herzeliya Medical Center, Israel
- Study coordinator: Michal Youngster, MD
- Email: michalyo@gmail.com
- Phone: +972-50-643-0111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting pregnancy outcomes after assisted reproduction using a machine-learning model
A machine-learning model will be tested to see if early beta-hCG levels can predict live birth and identify pregnancies at risk after IVF or FET (with exploratory look at IUI).
-
AI tool to analyze sperm and predict their ability to help IVF/ICSI succeed
This project will test an AI platform that analyzes semen samples from men providing sperm for IVF/ICSI to see if it can predict which samples have the best chance of supporting successful IVF/ICSI outcomes.
-
Red/near-infrared light to boost egg energy and improve IVF outcomes
This study will test whether briefly shining red/near-infrared light on eggs during IVF helps them make healthier embryos and raises pregnancy chances for people using their own oocytes.
-
Vitamin C to improve IVF outcomes for women with diminished ovarian reserve
This trial will test whether taking vitamin C during IVF improves pregnancy and live-birth chances for women with diminished ovarian reserve.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.